Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Viking Therapeutics (VKTX) EBT (2016 - 2025)

Historic EBT for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to -$90.8 million.

  • Viking Therapeutics' EBT fell 26279.32% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.3 million, marking a year-over-year decrease of 13932.5%. This contributed to the annual value of -$110.0 million for FY2024, which is 2817.25% down from last year.
  • Viking Therapeutics' EBT amounted to -$90.8 million in Q3 2025, which was down 26279.32% from -$65.5 million recorded in Q2 2025.
  • Viking Therapeutics' EBT's 5-year high stood at -$12.4 million during Q4 2021, with a 5-year trough of -$90.8 million in Q3 2025.
  • For the 5-year period, Viking Therapeutics' EBT averaged around -$27.4 million, with its median value being -$19.6 million (2022).
  • Its EBT has fluctuated over the past 5 years, first plummeted by 1044.42% in 2023, then crashed by 26279.32% in 2025.
  • Over the past 5 years, Viking Therapeutics' EBT (Quarter) stood at -$12.4 million in 2021, then crashed by 58.29% to -$19.6 million in 2022, then dropped by 25.72% to -$24.6 million in 2023, then crashed by 44.0% to -$35.4 million in 2024, then plummeted by 156.51% to -$90.8 million in 2025.
  • Its last three reported values are -$90.8 million in Q3 2025, -$65.5 million for Q2 2025, and -$45.6 million during Q1 2025.